Literature DB >> 24627090

Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B.

Y X Jia1, F Q Cui, L Li, D L Zhang, G M Zhang, F Z Wang, X H Gong, H Zheng, Z H Wu, N Miao, X J Sun, L Zhang, J J Lv, F Yang.   

Abstract

OBJECTIVES: The purpose of the study was to compare psychometric properties of the EQ-5D-5L (5L) and the EQ-5D-3L (3L) health outcomes assessment instruments in patients with hepatitis B in China.
METHODS: Patients, including hepatitis B virus carriers and those with active or inactive chronic hepatitis B, compensated cirrhosis, decompensated cirrhosis or hepatocellular carcinoma, answered a questionnaire composed of 5L, socio-demographic information, 3L, and the visual analog scale (VAS), respectively. After 1 week, a retest was conducted for inpatients. We compared acceptability, face validity, redistribution properties, convergent validity, known-group validity, discriminatory power, ceiling effect, test-retest reliability, and responsiveness of 5L and 3L.
RESULTS: A total of 369 outpatients and 276 inpatients were recruited for the first interview. Of the inpatients, 183 were used in the retest. Most patients preferred 5L-3L. The 3L-5L response pairs had an inconsistency rate of 2.4%. Correlation with the VAS was greater with 5L than with 3L. Age, education, and comorbidity were associated with health-related quality of life (HRQoL). 5L discriminated more infectious conditions than 3L. In all dimensions, the Shannon's index from 5L was larger while in three dimensions the Shannon's evenness index from 5L was slightly larger. The ceiling effect was reduced in 5L. In patients with stable health states, no significant difference was detected in the weighted kappa between 5L and 3L, but intraclass correlation coefficient of 5L was higher than that of 3L. In patients with improved health states, HRQoL was seen as increased in both 5L and 3L, without significant difference.
CONCLUSIONS: The EQ-5D-5L was more suitable than the EQ-5D-3L in the patients with hepatitis B in China.

Entities:  

Mesh:

Year:  2014        PMID: 24627090     DOI: 10.1007/s11136-014-0670-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

1.  Estimating an EQ-5D population value set: the case of Japan.

Authors:  Aki Tsuchiya; Shunya Ikeda; Naoki Ikegami; Shuzo Nishimura; Ikuro Sakai; Takashi Fukuda; Chisato Hamashima; Akinori Hisashige; Makoto Tamura
Journal:  Health Econ       Date:  2002-06       Impact factor: 3.046

Review 2.  A comparative review of four preference-weighted measures of health-related quality of life.

Authors:  Jacek A Kopec; Kevin D Willison
Journal:  J Clin Epidemiol       Date:  2003-04       Impact factor: 6.437

Review 3.  Methods and issues associated with the use of quality-adjusted life-years.

Authors:  Dennis A Revicki; William R Lenderking
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-02       Impact factor: 2.217

4.  Variation in Chinese population health related quality of life: results from a EuroQol study in Beijing, China.

Authors:  Hong Wang; David A Kindig; John Mullahy
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

5.  Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

Authors:  A Simon Pickard; Maria C De Leon; Thomas Kohlmann; David Cella; Sarah Rosenbloom
Journal:  Med Care       Date:  2007-03       Impact factor: 2.983

6.  Validation of the EQ-5D in a general population sample in urban China.

Authors:  Hong-Mei Wang; Donald L Patrick; Todd C Edwards; Anne M Skalicky; Hai-Yan Zeng; Wen-Wen Gu
Journal:  Qual Life Res       Date:  2011-04-20       Impact factor: 4.147

7.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Authors:  Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard
Journal:  Value Health       Date:  2012-05-24       Impact factor: 5.725

8.  Psychometric properties of the EQ-5D-5L in the general population of South Korea.

Authors:  Tae Hyup Kim; Min-Woo Jo; Sang-il Lee; Seon Ha Kim; Son Mi Chung
Journal:  Qual Life Res       Date:  2012-12-06       Impact factor: 4.147

9.  Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.

Authors:  Luciana Scalone; Roberta Ciampichini; Stefano Fagiuoli; Ivan Gardini; Francesco Fusco; Laura Gaeta; Anna Del Prete; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Qual Life Res       Date:  2012-11-29       Impact factor: 4.147

10.  Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008.

Authors:  Sun Sun; Jiaying Chen; Magnus Johannesson; Paul Kind; Ling Xu; Yaoguang Zhang; Kristina Burström
Journal:  Qual Life Res       Date:  2010-11-02       Impact factor: 4.147

View more
  46 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

2.  The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients.

Authors:  Chen-Wei Pan; Hong-Peng Sun; Xingzhi Wang; Qinghua Ma; Yong Xu; Nan Luo; Pei Wang
Journal:  Qual Life Res       Date:  2014-12-25       Impact factor: 4.147

3.  Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.

Authors:  Fanni Rencz; Peter L Lakatos; László Gulácsi; Valentin Brodszky; Zsuzsanna Kürti; Szilvia Lovas; János Banai; László Herszényi; Tamás Cserni; Tamás Molnár; Márta Péntek; Károly Palatka
Journal:  Qual Life Res       Date:  2018-09-17       Impact factor: 4.147

4.  Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011.

Authors:  M A Garcia-Gordillo; J C Adsuar; P R Olivares
Journal:  Qual Life Res       Date:  2015-10-19       Impact factor: 4.147

5.  Comparing the validity and responsiveness of the EQ-5D-5L to the Oxford hip and knee scores and SF-12 in osteoarthritis patients 1 year following total joint replacement.

Authors:  Barbara L Conner-Spady; Deborah A Marshall; Eric Bohm; Michael J Dunbar; Tom W Noseworthy
Journal:  Qual Life Res       Date:  2018-02-08       Impact factor: 4.147

6.  Validity of the EQ-5D-5L and reference norms for the Spanish population.

Authors:  Gimena Hernandez; Olatz Garin; Yolanda Pardo; Gemma Vilagut; Àngels Pont; Mónica Suárez; Montse Neira; Luís Rajmil; Inigo Gorostiza; Yolanda Ramallo-Fariña; Juan Cabases; Jordi Alonso; Montse Ferrer
Journal:  Qual Life Res       Date:  2018-05-16       Impact factor: 4.147

7.  EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.

Authors:  Mihir Gandhi; Marcus Ang; Kelvin Teo; Chee Wai Wong; Yvonne Chung-Hsi Wei; Rachel Lee-Yin Tan; Mathieu F Janssen; Nan Luo
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

8.  Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.

Authors:  Yuanxi Jia; Li Li; Fuqiang Cui; Dongliang Zhang; Guomin Zhang; Fuzhen Wang; Xiaohong Gong; Hui Zheng; Zhenhua Wu; Ning Miao; Xiaojin Sun; Li Zhang; Jingjing Lv; Feng Yang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty.

Authors:  Meridith E Greene; Kevin A Rader; Göran Garellick; Henrik Malchau; Andrew A Freiberg; Ola Rolfson
Journal:  Clin Orthop Relat Res       Date:  2015-11       Impact factor: 4.176

10.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.

Authors:  Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi
Journal:  Qual Life Res       Date:  2020-09-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.